will do my best:) many catalysts: expansion including regulatory approvals several countries
Total CGuard™ EPS sales increase 132%.
5th consecutive quarter of sequential double-digit growth
Ends Q1 with $4.6m of cash plus an additional $4.1m in net proceeds from capital raise that closed in Q2
“Having met previously with the FDA regarding our investigational device exemption (IDE) submission for CGuard™ EPS, we are now evaluating plans to restart the regulatory approval process in the United States. Concurrently, we are exploring other synergistic opportunities and product extensions that may allow us to leverage our distribution network and growing sales channels in Europe, Asia and Latin America.”
My posts are my opinion and should not be used as investment advice. Make your own decisions in your stock trades.
